The firm increased its full-year guidance to a new range of $1.34 billion to 1.36 billion from a previous range of $1.30 billion to $1.32 billion.

The company reported Q2 2026 revenue of $3.73 billion compared to $3.53 billion in the year-ago period, beating Wall Street's consensus estimate of $3.71 billion.

HHS OIG issued five recommendations, including refunding the federal government $18.5 million, as well as additional refunds for other potential overpayments.

The partners are also working together to validate the company's molecular testing technologies in various settings.

The Chicago-based company is developing a POC field-effect transistor (FET)-based analyzer that it plans initially to target to the fertility testing space.

The firm revised its revenue guidance for full-year 2026 to a range of $802 million to $806 million, and its net loss for the year to a range of $42 million to $34 million.

NEW YORK – As the liquid biopsy space has exploded in recent years, clinical laboratories are struggling to find sufficient staff to oversee and run these assays. Staffing is a problem for the ...

The platform combines machine learning and sample preparation techniques with the firm's proprietary Raman spectral databases.

An analyst acknowledged Abbott's diagnostics business faces some downside risks, but its medical technology business is buoyed by potential tailwinds.

The lab firm said it now expects full-year net revenue in the range of $11.95 billion to $12.05 billion, up from its previous guidance of $11.78 billion to $11.90 billion.

SimpleScreen is for adults 45 years of age and above at average risk for colorectal cancer and requires a simple blood draw. The test detects signals associated with colorectal cancer from cell-free ...